Novo Nordisk A/S: Saxenda® approved in Europe for the treatment of obesity
2015-03-23 · Novo Nordisk A/S · original novonordisk.com ↗
Bagsværd, Denmark, 23 March 2015 - Novo Nordisk today announced that the European Commission has granted marketing authorisation for Saxenda® (liraglutide 3 mg) for the treatment of obesity. The authorisation covers all 28 European Union (EU) member states. For further information Media: Mike Rulis +45 3079 3573 [email protected] Ken Inchausti (US) +1 609 514 8316 [email protected] Investors: Kasper Roseeuw Poulsen +45 3079 4303 [email protected] Melanie Raouzeos +45 3075 3479 [email protected] Daniel Bohsen +45 3079 6376 [email protected] Frank Daniel Mersebach (US) +1 609 235 8567 [email protected] Company announcement No 21 / 2015
The release as fetched from its publisher. novonordisk.com ↗